AC-1204

AC-1204
14
Sep

The AC-1204 Ketosis Strategy

Leveraging the physiological ketone system to provide fuel for the brain is a promising approach to addressing deficient glucose metabolism that is characteristic of Alzheimer’s disease.

AC-1204_graphic2

A Look at the Data

An improvement in cognition has been consistently shown across multiple clinical studies

Phase 2a Study

A single crossover designCircle_Stats_graphic

•Improvement in cognition observed in patients who do not carry the APOE4 gene, 90 minutes after single dose administration.

• Improvement in cognition correlates with increased levels of ketones.

• Rapid improvement is based on energetics as neuronal metabolism immediately utilizes the available ketones.

 

 

 

 

 

Phase 2b Study

A multi-center, double blind, placebo-controlled 90-day study in subjects with mild to moderate Alzheimer’s disease

55-APOE4_Patients_graphic

 

 

AC-1204 is in Phase 3 development to treat mild to moderate AD patients who do not carry the APOE4 gene.

Phase3_Progress_graphic

X